Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Efficacy, acceptability, and safety of adjunctive aripiprazole in treatment-resistant depression: a meta-analysis of randomized controlled trials.

Luan S, Wan H, Zhang L, Zhao H.

Neuropsychiatr Dis Treat. 2018 Feb 8;14:467-477. doi: 10.2147/NDT.S156619. eCollection 2018.

2.

Brain Structure and Function in Women with Comorbid Bipolar and Premenstrual Dysphoric Disorder.

Syan SK, Minuzzi L, Smith M, Costescu D, Allega OR, Hall GBC, Frey BN.

Front Psychiatry. 2018 Jan 10;8:301. doi: 10.3389/fpsyt.2017.00301. eCollection 2017.

3.

Effect of Metabolic Syndrome on Late-Life Depression: Associations with Disease Severity and Treatment Resistance.

Mulvahill JS, Nicol GE, Dixon D, Lenze EJ, Karp JF, Reynolds CF 3rd, Blumberger DM, Mulsant BH.

J Am Geriatr Soc. 2017 Dec;65(12):2651-2658. doi: 10.1111/jgs.15129.

PMID:
29235659
4.

Blunted amygdala activity is associated with depression severity in treatment-resistant depression.

Ferri J, Eisendrath SJ, Fryer SL, Gillung E, Roach BJ, Mathalon DH.

Cogn Affect Behav Neurosci. 2017 Dec;17(6):1221-1231. doi: 10.3758/s13415-017-0544-6.

PMID:
29063521
5.

Equivalent linear change in cognition between individuals with bipolar disorder and healthy controls over 5 years.

Ryan KA, Assari S, Angers K, Marshall DF, Hinrichs K, Easter R, Babu P, Pester BD, Langenecker SA, McInnis MG.

Bipolar Disord. 2017 Dec;19(8):689-697. doi: 10.1111/bdi.12532. Epub 2017 Sep 14.

PMID:
28906586
6.

How Effective Is Algorithm-Guided Treatment for Depressed Inpatients? Results from the Randomized Controlled Multicenter German Algorithm Project 3 Trial.

Adli M, Wiethoff K, Baghai TC, Fisher R, Seemüller F, Laakmann G, Brieger P, Cordes J, Malevani J, Laux G, Hauth I, Möller HJ, Kronmüller KT, Smolka MN, Schlattmann P, Berger M, Ricken R, Stamm TJ, Heinz A, Bauer M.

Int J Neuropsychopharmacol. 2017 Sep 1;20(9):721-730. doi: 10.1093/ijnp/pyx043.

7.

You'll feel better in the morning: slow wave activity and overnight mood regulation in interepisode bipolar disorder.

Soehner AM, Kaplan KA, Saletin JM, Talbot LS, Hairston IS, Gruber J, Eidelman P, Walker MP, Harvey AG.

Psychol Med. 2018 Jan;48(2):249-260. doi: 10.1017/S0033291717001581. Epub 2017 Jun 19.

8.

Prefrontal brain responsiveness to negative stimuli distinguishes familial risk for major depression from acute disorder.

Opel N, Redlich R, Grotegerd D, Dohm K, Zaremba D, Meinert S, Bürger C, Plümpe L, Alferink J, Heindel W, Kugel H, Zwanzger P, Arolt V, Dannlowski U.

J Psychiatry Neurosci. 2017 Sep;42(5):343-352.

9.

Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder.

Kadriu B, Gold PW, Luckenbaugh DA, Lener MS, Ballard ED, Niciu MJ, Henter ID, Park LT, De Sousa RT, Yuan P, Machado-Vieira R, Zarate CA Jr.

Mol Psychiatry. 2017 May 30. doi: 10.1038/mp.2017.109. [Epub ahead of print]

10.

The impact of obesity on neuropsychological functioning in adults with and without major depressive disorder.

Restivo MR, McKinnon MC, Frey BN, Hall GB, Syed W, Taylor VH.

PLoS One. 2017 May 5;12(5):e0176898. doi: 10.1371/journal.pone.0176898. eCollection 2017.

11.

Motor-Activity Markers of Circadian Timekeeping Are Related to Ketamine's Rapid Antidepressant Properties.

Duncan WC Jr, Slonena E, Hejazi NS, Brutsche N, Yu KC, Park L, Ballard ED, Zarate CA Jr.

Biol Psychiatry. 2017 Sep 1;82(5):361-369. doi: 10.1016/j.biopsych.2017.03.011. Epub 2017 Mar 28.

PMID:
28457485
12.

The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.

Carhart-Harris RL, Goodwin GM.

Neuropsychopharmacology. 2017 Oct;42(11):2105-2113. doi: 10.1038/npp.2017.84. Epub 2017 Apr 26.

PMID:
28443617
13.

A connectomic approach for subcallosal cingulate deep brain stimulation surgery: prospective targeting in treatment-resistant depression.

Riva-Posse P, Choi KS, Holtzheimer PE, Crowell AL, Garlow SJ, Rajendra JK, McIntyre CC, Gross RE, Mayberg HS.

Mol Psychiatry. 2017 Apr 11. doi: 10.1038/mp.2017.59. [Epub ahead of print]

14.

Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome.

Kiraly DD, Horn SR, Van Dam NT, Costi S, Schwartz J, Kim-Schulze S, Patel M, Hodes GE, Russo SJ, Merad M, Iosifescu DV, Charney DS, Murrough JW.

Transl Psychiatry. 2017 Mar 21;7(3):e1065. doi: 10.1038/tp.2017.31.

15.

Analysis of print news media framing of ketamine treatment in the United States and Canada from 2000 to 2015.

Zhang MW, Hong YX, Husain SF, Harris KM, Ho RC.

PLoS One. 2017 Mar 3;12(3):e0173202. doi: 10.1371/journal.pone.0173202. eCollection 2017.

16.

Sensory Processing Disorders are Associated with Duration of Current Episode and Severity of Side Effects.

Serafini G, Engel-Yeger B, Vazquez GH, Pompili M, Amore M.

Psychiatry Investig. 2017 Jan;14(1):51-57. doi: 10.4306/pi.2017.14.1.51. Epub 2016 Dec 29.

17.

Investigational drugs in recent clinical trials for treatment-resistant depression.

Garay RP, Zarate CA Jr, Charpeaud T, Citrome L, Correll CU, Hameg A, Llorca PM.

Expert Rev Neurother. 2017 Jun;17(6):593-609. doi: 10.1080/14737175.2017.1283217. Epub 2017 Jan 29. Review.

PMID:
28092469
18.

A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression.

Romijn AR, Rucklidge JJ, Kuijer RG, Frampton C.

Aust N Z J Psychiatry. 2017 Aug;51(8):810-821. doi: 10.1177/0004867416686694. Epub 2017 Jan 10.

19.

Repeated acupuncture treatments modulate amygdala resting state functional connectivity of depressive patients.

Wang X, Wang Z, Liu J, Chen J, Liu X, Nie G, Byun JS, Liang Y, Park J, Huang R, Liu M, Liu B, Kong J.

Neuroimage Clin. 2016 Jul 27;12:746-752. eCollection 2016.

20.

Supplemental Content

Support Center